Our attorneys have filed a mass tort lawsuit on behalf of individuals who took the blood thinner Xarelto (rivaroxaban) and suffered critical bleeding events. Pharmaceutical firms, which includes the makers of Xarelto, have a duty to make sure that their drugs are reasonably secure for use – and failure to accomplish so might be grounds for compensation. Our lawyers are functioning tough to obtain those hurt by the drug the compensation they may be entitled to.
Although bleeding is actually a widespread complication related with anticoagulants, it has been alleged that Xarelto is a lot more harmful than standard blood thinners since no antidote exists to reverse its blood-thinning effects. This signifies that, within the event of an emergency, patients might be at danger for irreversible bleeding problems, which includes life-threatening internal and gastrointestinal hemorrhaging.
In the event you or a loved one particular suffered a severe bleeding event after taking Xarelto, you may have legal recourse. For much more information, contact us today to have your case reviewed, free of charge.
Compensation Possibilities
xarelto-compensation-photoThe plaintiffs in these lawsuits are seeking compensation from Bayer and Janssen for previous http://xareltolegalinformation.bitbucket.org/ and future healthcare bills, lost wages, discomfort and suffering and, in cases of death, funeral costs. In addition, they’re searching for punitive damages, which are usually awarded to punish the defendant and deter other businesses from acting similarly.
Why Are Lawsuits Becoming Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is harmful and defective. The plaintiffs claim that, unlike traditional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Due to the fact of this, the lawsuits claim, doctors have no effective means of stopping Xarelto users from bleeding within the occasion of an emergency. Plaintiffs in the lawsuits allege significant and fatal injuries, including cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of Xarelto marketed the drug as a superior within the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a secure anticoagulant option.
Doctors and medical staff were not properly made aware of methods to stabilize and treat a Xarelto user within the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to severe bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing hazardous clotting.
Visit this page for more data on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys within the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.